Review finds no consistent link between GLP-1 drugs and wet age-related macular degeneration
Human observational studies have reported higher, lower, and unchanged risk, leaving the possible association uncertain.
Very low evidenceReviewInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Researchers reviewed direct clinical studies, safety-report data, diabetic eye-disease research, and proposed biological explanations for a possible connection between GLP-1 receptor agonists and neovascular age-related macular degeneration. The review emphasized that the direct clinical evidence is more important than laboratory or mechanistic explanations, and that those explanations do not establish harm or protection in people.
The reviewed evidence included a large Canadian cohort of older adults with diabetes in which most GLP-1 receptor exposure involved semaglutide. That study reported a higher rate of newly diagnosed neovascular age-related macular degeneration, but later studies did not consistently reproduce the finding. Differences in patient groups, comparison groups, adjustment for other risk factors, eye-care use, medication exposure definitions, and outcome recording may help explain the disagreement.
What the review examined
The article was a review of emerging human clinical evidence on whether GLP-1 receptor agonist exposure is associated with neovascular age-related macular degeneration among people with type 2 diabetes. It also considered pharmacovigilance reports, studies of diabetic retinal disease, and proposed mechanisms involving inflammation, oxidative stress, blood-vessel function, and angiogenic signaling. The review was not itself a randomized clinical trial and did not provide a new patient-level study sample. It discussed several observational studies, including a population-based cohort of 139,002 adults aged 66 years or older with diabetes: 46,334 had used a GLP-1 receptor agonist for at least six months and 92,668 matched people had not used one.
Key conclusions
The reviewed clinical evidence was inconsistent. In the large Canadian cohort, neovascular age-related macular degeneration was diagnosed in 0.2% of GLP-1 receptor agonist users and 0.1% of matched nonusers, with an adjusted hazard ratio of 2.21 and a 95% confidence interval of 1.65 to 2.96. However, another national cohort reported lower incidence among GLP-1 receptor agonist users, and two large active-comparator analyses found no significant increase in risk, including a multi-database study of semaglutide using both new-user and self-controlled analyses. Overall, the review concluded that the evidence does not establish a causal association or show a consistent increase in risk across the drug class. Smaller effects limited to particular medicines or patient groups cannot yet be excluded.
Where this may apply
The findings are most relevant to people with type 2 diabetes who are similar to the populations in the reviewed observational studies, particularly older adults represented in some cohorts. They should not be assumed to apply equally to younger people, people without diabetes, or every individual GLP-1 receptor agonist and treatment pattern. The review does not establish a patient-specific risk, and evidence from pharmacovigilance reports, diabetic retinal disease studies, or biological mechanisms cannot by itself be treated as evidence about neovascular age-related macular degeneration in a particular person.
The significance
GLP-1 receptor agonists are used in people with type 2 diabetes, while neovascular age-related macular degeneration is an important eye condition in older adults. Clarifying a possible association matters because diabetes, aging, metabolic factors, and patterns of eye-care use can overlap and make observational results difficult to interpret. The review suggests that the current evidence is too inconsistent to determine whether GLP-1 receptor agonists affect this eye condition. Biological explanations and findings from diabetic retinal disease research provide context only; they do not demonstrate an effect on neovascular age-related macular degeneration in humans.
Limitations & evidence assessment
The central limitation is that the evidence reviewed was largely retrospective and observational, so differences between medicine users and nonusers may explain some findings and causation cannot be established. The studies differed in their populations, comparison groups, medication exposure definitions, control of confounding factors, eye-care surveillance, and methods for identifying the eye disease. Some analyses were dominated by semaglutide exposure, making results for individual medicines uncertain. The available evidence also lacked consistent detailed information on dose, treatment duration, cumulative exposure, treatment changes, diabetes control over time, imaging-confirmed eye findings, latency, and potentially susceptible subgroups. The review itself was not described as a systematic review or meta-analysis, and the abstract does not provide a formal pooled estimate across studies.
Why this evidence level: Methodology unclear from available metadata; treated as preliminary.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Current Ophthalmology Reports · 2026 · DOI: 10.1007/s40135-026-00357-w
A prospective, multicenter phase II trial examined whether removing only the treated tumor area through the anus could preserve the rectum in people with locally advanced rectal cancer who responded well to chemoradiotherapy. Among 80 participants, three-year disease-free survival was 84.8%, and local recurrence occurred in 5.0% during the reported follow-up. Because everyone received local excision and there was no comparison group, the findings do not establish that this approach is as effective as more extensive surgery.
This retrospective human study compared a visual CT scoring method with an automated computer analysis for tracking fibrosing interstitial lung disease. Among 92 people followed with CT scans and lung-function tests, both approaches were associated with changes in lung function and signs of disease progression. The study does not show that either method improves treatment or patient outcomes.
A systematic review and meta-analysis examined how silver diamine fluoride affects human dental pulp cells in laboratory studies. Across seven in vitro studies, higher concentrations were associated with lower cell viability, but these findings do not show how the material affects dental pulp in people.
